AU724086B2 - Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride - Google Patents

Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride Download PDF

Info

Publication number
AU724086B2
AU724086B2 AU41288/97A AU4128897A AU724086B2 AU 724086 B2 AU724086 B2 AU 724086B2 AU 41288/97 A AU41288/97 A AU 41288/97A AU 4128897 A AU4128897 A AU 4128897A AU 724086 B2 AU724086 B2 AU 724086B2
Authority
AU
Australia
Prior art keywords
dosage form
coated
beads
polymer
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU41288/97A
Other languages
English (en)
Other versions
AU4128897A (en
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of AU4128897A publication Critical patent/AU4128897A/en
Application granted granted Critical
Publication of AU724086B2 publication Critical patent/AU724086B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU41288/97A 1996-09-12 1997-09-08 Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride Ceased AU724086B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9619074 1996-09-12
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride

Publications (2)

Publication Number Publication Date
AU4128897A AU4128897A (en) 1998-04-02
AU724086B2 true AU724086B2 (en) 2000-09-14

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41288/97A Ceased AU724086B2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride

Country Status (22)

Country Link
EP (1) EP0929301A2 (id)
JP (1) JP2001500150A (id)
KR (1) KR20000036039A (id)
CN (2) CN1235544A (id)
AR (1) AR008176A1 (id)
AU (1) AU724086B2 (id)
BR (1) BR9711734A (id)
CA (1) CA2265661A1 (id)
CO (1) CO5031291A1 (id)
CZ (1) CZ83299A3 (id)
GB (1) GB9619074D0 (id)
HU (1) HUP9904401A3 (id)
ID (1) ID19589A (id)
IL (1) IL128781A0 (id)
MA (1) MA24359A1 (id)
NO (1) NO991194L (id)
NZ (1) NZ334268A (id)
PE (1) PE2499A1 (id)
PL (1) PL332074A1 (id)
TR (1) TR199900505T2 (id)
WO (1) WO1998010762A2 (id)
ZA (1) ZA978133B (id)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
AU748396C (en) * 1998-03-11 2003-01-23 Smithkline Beecham Corporation Composition
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
EP1628642B2 (en) * 2003-05-14 2013-01-23 Aptalis Pharma Limited Controlled drug release composition resistant to in vivo mechanic stress
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
PL1789021T3 (pl) 2004-08-13 2012-04-30 Boehringer Ingelheim Int Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392803A1 (en) * 1989-04-13 1990-10-17 Beecham Group p.l.c. Novel compounds
WO1996012486A1 (en) * 1994-10-25 1996-05-02 Smithkline Beecham P.L.C. Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392803A1 (en) * 1989-04-13 1990-10-17 Beecham Group p.l.c. Novel compounds
WO1996012486A1 (en) * 1994-10-25 1996-05-02 Smithkline Beecham P.L.C. Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease

Also Published As

Publication number Publication date
BR9711734A (pt) 1999-08-24
ID19589A (id) 1998-07-23
CO5031291A1 (es) 2001-04-27
EP0929301A2 (en) 1999-07-21
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
CN1235544A (zh) 1999-11-17
TR199900505T2 (id) 1999-06-21
PL332074A1 (en) 1999-08-30
CN1446535A (zh) 2003-10-08
NO991194D0 (no) 1999-03-11
AR008176A1 (es) 1999-12-09
CZ83299A3 (cs) 1999-08-11
HUP9904401A3 (en) 2001-03-28
KR20000036039A (ko) 2000-06-26
NO991194L (no) 1999-03-11
WO1998010762A3 (en) 1998-06-04
MA24359A1 (fr) 1998-07-01
CA2265661A1 (en) 1998-03-19
NZ334268A (en) 2000-10-27
ZA978133B (en) 1999-04-12
GB9619074D0 (en) 1996-10-23
WO1998010762A2 (en) 1998-03-19
JP2001500150A (ja) 2001-01-09
AU4128897A (en) 1998-04-02
PE2499A1 (es) 1999-03-24

Similar Documents

Publication Publication Date Title
US6468560B2 (en) Controlled release dosage form of [R-(Z)]-α-(methoxyimino)-α-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride
US8703186B2 (en) Abuse-resistant oral dosage forms and method of use thereof
US5807579A (en) Pseudoephedrine combination pharmaceutical compositions
US7790200B2 (en) Formulation and process for drug loaded cores
US20030133982A1 (en) Zero-order sustained release dosage forms and method of making same
CA2717456A1 (en) Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
AU2008288106B2 (en) Extended release compositions comprising mycophenolate sodium and processes thereof
WO2010140111A1 (en) Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
AU724086B2 (en) Controlled release dosage form of (R-(Z))-alpha- (methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride
US20030224045A1 (en) Combination immediate release sustained release levodopa/carbidopa dosage forms
US20030099710A1 (en) Granule modulating hydrogel system
US6238703B1 (en) Controlled release oral dosage form of ketoprofen
US20080206335A1 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
US20090220593A1 (en) Extended release dosage forms of quetiapine
AU782059B2 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
US7060293B1 (en) Powder-layered oral dosage forms
US20040228918A1 (en) Granule modulating hydrogel system
MXPA99002404A (en) Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2. 2]oct-3-yl)acetonitrile monohydrochloride
CN118265524A (zh) 黄酮哌酯的控制释放制剂及其制备方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired